Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Receivables (2016 - 2025)

Guided Therapeutics' Receivables history spans 16 years, with the latest figure at $4000.0 for Q4 2025.

  • On a quarterly basis, Receivables rose 33.33% to $4000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $4000.0, a 33.33% increase, with the full-year FY2025 number at $4000.0, up 33.33% from a year prior.
  • Receivables hit $4000.0 in Q4 2025 for Guided Therapeutics, down from $6000.0 in the prior quarter.
  • Over the last five years, Receivables for GTHP hit a ceiling of $165.1 million in Q1 2022 and a floor of $2000.0 in Q3 2024.
  • Historically, Receivables has averaged $15.8 million across 5 years, with a median of $7721.0 in 2023.
  • Biggest five-year swings in Receivables: surged 130955.56% in 2022 and later tumbled 99.97% in 2023.
  • Tracing GTHP's Receivables over 5 years: stood at $171153.0 in 2021, then tumbled by 47.83% to $89296.0 in 2022, then crashed by 91.67% to $7442.0 in 2023, then crashed by 59.69% to $3000.0 in 2024, then soared by 33.33% to $4000.0 in 2025.
  • Business Quant data shows Receivables for GTHP at $4000.0 in Q4 2025, $6000.0 in Q3 2025, and $8000.0 in Q2 2025.